Pancreas Cancer Specialized Program of Research Excelle*

描述(由申请人提供)： 这一胰腺癌专业卓越研究计划(SPORT)的目标是将杰出的假设驱动的基础研究转化为拯救生命的临床治疗。胰腺癌是一种毁灭性的癌症，导致患者死亡的原因不仅是因为它可能具有极强的侵袭性，还因为它被诊断得很晚。这个孢子是乔治敦大学、盖辛格健康系统和INDIVUMED德国研究所与一个德国医院财团的独特合作，该财团汇集了一家杰出的学术机构、一个大型的地区性医疗保健系统以及一个德国基础和临床研究系统，以解决胰腺癌的生物学和临床护理问题。项目1的重点是抑制多营养素，一种新的肝素结合生长因子，促进胰腺癌的侵袭和转移。项目2专注于神经肿瘤细胞相互作用模型中神经调节蛋白和多核营养因子的作用，目的是开发方法来阻止恶性胰腺细胞的神经侵袭，最终可能有助于疾病的缓解。项目3专注于最近的发现，即抑制胰腺癌细胞和邻近内皮细胞内的核受体辅助激活因子AIB1可能会阻断多种生长因子的信号转导以促进细胞凋亡。发生在高达90%的胰腺癌中的ras/MAP激酶通路的激活是项目4中辐射增敏新方法的重点。乔治敦大学的研究人员已经开发出一种已经处于I期试验的rafl反义抑制剂，并已经开发出该通路中的其他互补分子靶点。此外，该孢子正在开发基础设施和资源，以从患者(胰腺肿瘤库和血清检测和分子鉴定核心)获取组织和体液，预计每年将进行120次根治性切除。孢子将利用生物统计学核心来确保所有项目都有适当的设计、分析方法和用于报告患者结果的综合数据库。此外，该孢子将支持旨在产生早期发现的新知识和方法的开发项目，并促进致力于胰腺癌转化研究的职业发展轨迹的发展。该孢子还与其他机构的孢子以及NCI和NIH资助的其他项目建立了互动，以促进积极开发控制胰腺癌的新疗法。

DESCRIPTION (provided by applicant): The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90 percent of pancreas cancer is the focus for novel approaches to radiation sensitization in Project 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer.